1
|
Li L, Wang M, Hao J, Han J, Fu T, Bai J, Tian M, Jin N, Zhu G, Li C. Mucosal IgA response elicited by intranasal immunization of Lactobacillus plantarum expressing surface-displayed RBD protein of SARS-CoV-2. Int J Biol Macromol 2021; 190:409-416. [PMID: 34499954 PMCID: PMC8421092 DOI: 10.1016/j.ijbiomac.2021.08.232] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2021] [Revised: 08/30/2021] [Accepted: 08/31/2021] [Indexed: 12/01/2022]
Abstract
Coronavirus Disease 2019 (COVID-19) caused by a novel betacoronavirus SARS-CoV-2 has been an ongoing global pandemic. Several vaccines have been developed to control the COVID-19, but the potential effectiveness of the mucosal vaccine remains to be documented. In this study, we constructed a recombinant L. plantarum LP18:RBD expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein via the surface anchoring route. The amount of the RBD protein was maximally expressed under the culture condition with 200 ng/mL of inducer at 33 °C for 6 h. Further, we evaluated the immune response in mice via the intranasal administration of LP18:RBD. The results showed that the LP18:RBD significantly elicited RBD-specific mucosal IgA antibodies in respiratory tract and intestinal tract. The percentages of CD3 + CD4+ T cells in spleens of mice administrated with the LP18:RBD were also significantly increased. This indicated that LP18:RBD could induce a humoral immune response at the mucosa, and it could be used as a mucosal vaccine candidate against the SARS-CoV-2 infection. We provided the first experimental evidence that the recombinant L. plantarum LP18:RBD could initiate immune response in vivo, which implies that the mucosal immunization using recombinant LAB system could be a promising vaccination strategy to prevent the COVID-19 pandemic.
Collapse
Affiliation(s)
- Letian Li
- Research Unit of Key Technologies for Prevention and Control of Virus Zoonoses, Chinese Academy of Medical Sciences, Changchun Institute of Veterinary Medicine, Chinese Academy of Agricultural Sciences, Changchun 130122, China
| | - Maopeng Wang
- Institute of Virology, Wenzhou University, Wenzhou 325035, China
| | - Jiayi Hao
- Research Unit of Key Technologies for Prevention and Control of Virus Zoonoses, Chinese Academy of Medical Sciences, Changchun Institute of Veterinary Medicine, Chinese Academy of Agricultural Sciences, Changchun 130122, China; College of Veterinary Medicine, Jilin Agricultural University, Changchun 130118, China
| | - Jicheng Han
- Academician Workstation of Jilin Province, Changchun University of Chinese Medicine, Changchun 130021, China
| | - Tingting Fu
- Research Unit of Key Technologies for Prevention and Control of Virus Zoonoses, Chinese Academy of Medical Sciences, Changchun Institute of Veterinary Medicine, Chinese Academy of Agricultural Sciences, Changchun 130122, China
| | - Jieying Bai
- Institute of Molecular Medicine, Peking University, Beijing 100871, China
| | - Mingyao Tian
- Research Unit of Key Technologies for Prevention and Control of Virus Zoonoses, Chinese Academy of Medical Sciences, Changchun Institute of Veterinary Medicine, Chinese Academy of Agricultural Sciences, Changchun 130122, China
| | - Ningyi Jin
- Research Unit of Key Technologies for Prevention and Control of Virus Zoonoses, Chinese Academy of Medical Sciences, Changchun Institute of Veterinary Medicine, Chinese Academy of Agricultural Sciences, Changchun 130122, China; Academician Workstation of Jilin Province, Changchun University of Chinese Medicine, Changchun 130021, China
| | - Guangze Zhu
- Academician Workstation of Jilin Province, Changchun University of Chinese Medicine, Changchun 130021, China.
| | - Chang Li
- Research Unit of Key Technologies for Prevention and Control of Virus Zoonoses, Chinese Academy of Medical Sciences, Changchun Institute of Veterinary Medicine, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
| |
Collapse
|
2
|
Cárcamo-Calvo R, Muñoz C, Buesa J, Rodríguez-Díaz J, Gozalbo-Rovira R. The Rotavirus Vaccine Landscape, an Update. Pathogens 2021; 10:520. [PMID: 33925924 PMCID: PMC8145439 DOI: 10.3390/pathogens10050520] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 04/21/2021] [Accepted: 04/23/2021] [Indexed: 11/17/2022] Open
Abstract
Rotavirus is the leading cause of severe acute childhood gastroenteritis, responsible for more than 128,500 deaths per year, mainly in low-income countries. Although the mortality rate has dropped significantly since the introduction of the first vaccines around 2006, an estimated 83,158 deaths are still preventable. The two main vaccines currently deployed, Rotarix and RotaTeq, both live oral vaccines, have been shown to be less effective in developing countries. In addition, they have been associated with a slight risk of intussusception, and the need for cold chain maintenance limits the accessibility of these vaccines to certain areas, leaving 65% of children worldwide unvaccinated and therefore unprotected. Against this backdrop, here we review the main vaccines under development and the state of the art on potential alternatives.
Collapse
Affiliation(s)
- Roberto Cárcamo-Calvo
- Department of Microbiology, School of Medicine, University of Valencia, Av. Blasco Ibañez 17, 46010 Valencia, Spain; (R.C.-C.); (C.M.); (J.B.)
| | - Carlos Muñoz
- Department of Microbiology, School of Medicine, University of Valencia, Av. Blasco Ibañez 17, 46010 Valencia, Spain; (R.C.-C.); (C.M.); (J.B.)
| | - Javier Buesa
- Department of Microbiology, School of Medicine, University of Valencia, Av. Blasco Ibañez 17, 46010 Valencia, Spain; (R.C.-C.); (C.M.); (J.B.)
- Instituto de Investigación INCLIVA, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain
| | - Jesús Rodríguez-Díaz
- Department of Microbiology, School of Medicine, University of Valencia, Av. Blasco Ibañez 17, 46010 Valencia, Spain; (R.C.-C.); (C.M.); (J.B.)
- Instituto de Investigación INCLIVA, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain
| | - Roberto Gozalbo-Rovira
- Department of Microbiology, School of Medicine, University of Valencia, Av. Blasco Ibañez 17, 46010 Valencia, Spain; (R.C.-C.); (C.M.); (J.B.)
- Instituto de Investigación INCLIVA, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain
| |
Collapse
|
3
|
Lopez-Guerrero DV, Arias N, Gutierrez-Xicotencatl L, Chihu-Amparan L, González A, Pedroza-Saavedra A, Rosas-Salgado G, Villegas-Garcia JC, Badillo-Godinez O, Fernandez G, Lopez S, Esquivel-Guadarrama F. Enhancement of VP6 immunogenicity and protective efficacy against rotavirus by VP2 in a genetic immunization. Vaccine 2018; 36:3072-3078. [PMID: 28465094 DOI: 10.1016/j.vaccine.2017.03.104] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2016] [Revised: 02/08/2017] [Accepted: 03/31/2017] [Indexed: 12/15/2022]
Abstract
VP2/VP6 virus like particles (VLPs) are very effective in inducing protection against the rotavirus infection in animal models. Individually, VP6 can also induce protection. However, there is no information about the immunogenicity of VP2. The aim of this work was to evaluate the efficacy of DNA vaccines codifying for VP2 or VP6, alone or combined, to induce protection against the rotavirus infection. Murine rotavirus VP2 and VP6 genes were cloned into the pcDNA3 vector. Adult BALB/c mice were inoculated three times by intramuscular (i.m.) injections with 100 or 200µg of pcDNA3-VP2 or pcDNA3-VP6 alone or co-administered with 100µg of pcDNA3-VP2/100µg of pcDNA3-VP6. Two weeks after the last inoculation, mice were challenged with the wild type murine rotavirus strain epizootic diarrhea of infant mice (EDIMwt). We found that both plasmids, pcDNA3-VP2 and pcDNA3-VP6, were able to induce rotavirus-specific serum antibodies, but not intestinal rotavirus-specific IgA; only 200µg of pcDNA3-VP6 induced 35% protection against the infection. A similar level of protection was found when mice were co-administered with 100µg of pcDNA3-VP2/100µg of pcDNA3-VP6 (1:1 ratio). However, the best protection (up to 58%) occurred when mice were inoculated with 10µg of pcDNA3-VP2/100µg of pcDNA3-VP6 (1:10 ratio). These results indicate that the DNA plasmid expressing VP6 is a better vaccine candidate that the one expressing VP2. However, when co-expressed, VP2 potentiates the immunogenicity and protective efficacy of VP6.
Collapse
Affiliation(s)
- D V Lopez-Guerrero
- Facultad de Medicina, Universidad Autonoma del Estado de Morelos, Cuernavaca, Morelos, Mexico
| | - N Arias
- Facultad de Medicina, Universidad Autonoma del Estado de Morelos, Cuernavaca, Morelos, Mexico
| | - L Gutierrez-Xicotencatl
- Centro de Investigaciones Sobre Enfermedades Infecciosas, INSP, SSA, Cuernavaca, Morelos, Mexico
| | - L Chihu-Amparan
- Centro de Investigaciones Sobre Enfermedades Infecciosas, INSP, SSA, Cuernavaca, Morelos, Mexico
| | - A González
- Centro de Investigacion en Dinamica Celular, Universidad Autonoma del Estado de Morelos, Cuernavaca, Morelos, Mexico
| | - A Pedroza-Saavedra
- Centro de Investigaciones Sobre Enfermedades Infecciosas, INSP, SSA, Cuernavaca, Morelos, Mexico
| | - G Rosas-Salgado
- Facultad de Medicina, Universidad Autonoma del Estado de Morelos, Cuernavaca, Morelos, Mexico
| | - J C Villegas-Garcia
- Facultad de Medicina, Universidad Autonoma del Estado de Morelos, Cuernavaca, Morelos, Mexico
| | - O Badillo-Godinez
- Facultad de Medicina, Universidad Autonoma del Estado de Morelos, Cuernavaca, Morelos, Mexico; Centro de Investigaciones Sobre Enfermedades Infecciosas, INSP, SSA, Cuernavaca, Morelos, Mexico
| | - G Fernandez
- Instituto de Biotecnologia-UNAM, Cuernavaca, Morelos, Mexico
| | - S Lopez
- Instituto de Biotecnologia-UNAM, Cuernavaca, Morelos, Mexico
| | - F Esquivel-Guadarrama
- Facultad de Medicina, Universidad Autonoma del Estado de Morelos, Cuernavaca, Morelos, Mexico.
| |
Collapse
|
4
|
Badillo-Godinez O, Gutierrez-Xicotencatl L, Plett-Torres T, Pedroza-Saavedra A, Gonzalez-Jaimes A, Chihu-Amparan L, Maldonado-Gama M, Espino-Solis G, Bonifaz LC, Esquivel-Guadarrama F. Targeting of rotavirus VP6 to DEC-205 induces protection against the infection in mice. Vaccine 2015; 33:4228-37. [PMID: 25850020 DOI: 10.1016/j.vaccine.2015.03.080] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2014] [Revised: 03/17/2015] [Accepted: 03/24/2015] [Indexed: 01/15/2023]
Abstract
Rotavirus (RV) is the primary etiologic agent of severe gastroenteritis in human infants. Although two attenuated RV-based vaccines have been licensed to be applied worldwide, they are not so effective in low-income countries, and the induced protection mechanisms have not been clearly established. Thus, it is important to develop new generation vaccines that induce long lasting heterotypic immunity. VP6 constitutes the middle layer protein of the RV virion. It is the most conserved protein and it is the target of protective T-cells; therefore, it is a potential candidate antigen for a new generation vaccine against the RV infection. We determined whether targeting the DEC-205 present in dendritic cells (DCs) with RV VP6 could induce protection at the intestinal level. VP6 was cross-linked to a monoclonal antibody (mAb) against murine DEC-205 (αDEC-205:VP6), and BALB/c mice were inoculated subcutaneously (s.c.) twice with the conjugated containing 1.5 μg of VP6 in the presence of polyinosinic-polycytidylic acid (Poly I:C) as adjuvant. As controls and following the same protocol, mice were immunized with ovalbumin (OVA) cross-linked to the mAb anti-DEC-205 (αDEC-205:OVA), VP6 cross-linked to a control isotype mAb (Isotype:VP6), 3 μg of VP6 alone, Poly I:C or PBS. Two weeks after the last inoculation, mice were orally challenged with a murine RV. Mice immunized with α-DEC-205:VP6 and VP6 alone presented similar levels of serum Abs to VP6 previous to the virus challenge. However, after the virus challenge, only α-DEC-205:VP6 induced up to a 45% IgA-independent protection. Memory T-helper (Th) cells from the spleen and the mesenteric lymph node (MLN) showed a Th1-type response upon antigen stimulation in vitro. These results show that when VP6 is administered parenterally targeting DEC-205, it can induce protection at the intestinal level at a very low dose, and this protection may be Th1-type cell dependent.
Collapse
Affiliation(s)
- O Badillo-Godinez
- Laboratorio de Inmunidad Viral, Facultad de Medicina, UAEM, Cuernavaca, MOR, Mexico; Facultad de Ciencias, UAEM, Cuernavaca, MOR, Mexico
| | | | - T Plett-Torres
- CISEI-Instituto Nacional de Salud Publica, Cuernavaca, MOR, Mexico
| | | | | | - L Chihu-Amparan
- CISEI-Instituto Nacional de Salud Publica, Cuernavaca, MOR, Mexico
| | - M Maldonado-Gama
- CISEI-Instituto Nacional de Salud Publica, Cuernavaca, MOR, Mexico
| | - G Espino-Solis
- Instituto de Biotecnologia, UNAM, Cuernavaca, MOR, Mexico
| | - L C Bonifaz
- Unidad de Inmunohistoquimica, CMN, Hospital Siglo XXI, IMSS, Mexico, D.F., Mexico
| | - F Esquivel-Guadarrama
- Laboratorio de Inmunidad Viral, Facultad de Medicina, UAEM, Cuernavaca, MOR, Mexico.
| |
Collapse
|
5
|
|
6
|
Immune markers and correlates of protection for vaccine induced immune responses. Vaccine 2012; 30:4907-20. [PMID: 22658928 DOI: 10.1016/j.vaccine.2012.05.049] [Citation(s) in RCA: 120] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2012] [Revised: 05/15/2012] [Accepted: 05/19/2012] [Indexed: 12/15/2022]
Abstract
Vaccines have been a major innovation in the history of mankind and still have the potential to address the challenges posed by chronic intracellular infections including tuberculosis, HIV and malaria which are leading causes of high morbidity and mortality across the world. Markers of an appropriate humoral response currently remain the best validated correlates of protective immunity after vaccination. Despite advancements in the field of immunology over the past few decades currently there are, however, no sufficiently validated immune correlates of vaccine induced protection against chronic infections in neither human nor veterinary medicine. Technological and conceptual advancements within cell-mediated immunology have led to a number of new immunological read-outs with the potential to emerge as correlates of vaccine induced protection. For T(H)1 type responses, antigen-specific production of interferon-gamma (IFN-γ) has been promoted as a quantitative marker of protective cell-mediated immune responses over the past couple of decades. More recently, however, evidence from several infections has pointed towards the quality of the immune response, measured through increased levels of antigen-specific polyfunctional T cells capable of producing a triad of relevant cytokines, as a better correlate of sustained protective immunity against this type of infections. Also the possibilities to measure antigen-specific cytotoxic T cells (CTL) during infection or in response to vaccination, through recombinant major histocompatibility complex (MHC) class I tetramers loaded with relevant peptides, has opened a new vista to include CTL responses in the evaluation of protective immune responses. Here, we review different immune markers and new candidates for correlates of a protective vaccine induced immune response against chronic infections and how successful they have been in defining the protective immunity in human and veterinary medicine.
Collapse
|
7
|
Oral immunization of mice with Lactococcus lactis expressing the rotavirus VP8* protein. Biotechnol Lett 2011; 33:1169-75. [PMID: 21302132 DOI: 10.1007/s10529-011-0551-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2010] [Accepted: 01/25/2011] [Indexed: 10/18/2022]
Abstract
The efficacy of recombinant Lactococcus lactis as a delivery vehicle for a rotavirus antigen was evaluated in a mouse model. The rotavirus VP8* protein was expressed intracellularly and extracellularly in L. lactis wild type and in an alr mutant deficient in alanine racemase activity, necessary for the synthesis of the cell-wall component D: -alanine. When the mucosal immune response was evaluated by measuring VP8*-specific IgA antibody in faeces, wild-type L. lactis triggered a low IgA synthesis only when the secreting strain was used. In contrast, VP8*-specific IgA was detected in faeces of both groups of mice orally given the alr mutant expressing extracellular VP8* and intracellular VP8*, which reached levels similar to that obtained with the wild type secreting strain. However, oral administration of the recombinant strains did not induce serum IgG or IgA responses. L. lactis cell-wall mutants may therefore provide certain advantages when low-antigenic proteins are expressed intracellularly. However, the low immune response obtained by using this antigen-bacterial host combination prompts to the use of new strains and vaccination protocols in order to develop acceptable rotavirus immunization levels.
Collapse
|
8
|
Zhou H, Guo L, Wang M, Qu J, Zhao Z, Wang J, Hung T. Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice. Virol J 2011; 8:3. [PMID: 21205330 PMCID: PMC3024956 DOI: 10.1186/1743-422x-8-3] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2010] [Accepted: 01/05/2011] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND Rotavirus (RV) is the main cause of severe gastroenteritis in children. An effective vaccination regime against RV can substantially reduce morbidity and mortality. Previous studies have demonstrated the efficacy of virus-like particles formed by RV VP2 and VP6 (VLP2/6), as well as that of recombinant adenovirus expressing RV VP6 (rAd), in eliciting protective immunities against RV. However, the efficacy of such prime-boost strategy, which incorporates VLP and rAd in inducing protective immunities against RV, has not been addressed. We assessed the immune effects of different regimens in mice, including rAd prime-VLP2/6 boost (rAd+VLP), VLP2/6 prime-rAd boost (VLP+rAd), rAd alone, and VLP alone. RESULTS Mice immunized with the VLP+rAd regimen elicit stronger humoral, mucosal, and cellular immune responses than those immunized with other regimens. RV challenging experiments showed that the highest reduction (92.9%) in viral shedding was achieved in the VLP+rAd group when compared with rAd+VLP (25%), VLP alone (75%), or rAd alone (40%) treatment groups. The reduction in RV shedding in mice correlated with fecal IgG (r = 0.95773, P = 0.04227) and IgA (r = 0.96137, P = 0.038663). CONCLUSIONS A VLP2/6 prime-rAd boost regimen is effective in conferring immunoprotection against RV challenge in mice. This finding may lay the groundwork for an alternative strategy in novel RV vaccine development.
Collapse
Affiliation(s)
- Hongli Zhou
- State Key Laboratory for Molecular Virology and Genetic Engineering, Institute of Pathogen Biology, Chinese Academy Medical Sciences & Peking Union Medical College, Dong Dan San Tiao, Beijing 100730, PR China
| | | | | | | | | | | | | |
Collapse
|
9
|
Oral vaccination with the porcine rotavirus VP4 outer capsid protein expressed by Lactococcus lactis induces specific antibody production. J Biomed Biotechnol 2010; 2010:708460. [PMID: 20625406 PMCID: PMC2896853 DOI: 10.1155/2010/708460] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2009] [Revised: 12/19/2009] [Accepted: 03/26/2010] [Indexed: 12/28/2022] Open
Abstract
The objective of this study to design a delivery system resistant to the gastrointestinal environment for oral vaccine against porcine rotavirus. Lactococcus lactis NZ9000 was transformed with segments of vP4 of the porcine rotavirus inserted into the pNZ8112 surface-expression vector, and a recombinant L. lactis expressing VP4 protein was constructed. An approximately 27 kDa VP4 protein was confirmed by SDS-PAGE , Western blot and immunostaining analysis. BALB/c mice were immunized orally with VP4-expression recombinant L. lactis and cellular, mucosal and systemic humoral immune responses were examined. Specific anti-VP4 secretory IgA and IgG were found in feces, ophthalmic and vaginal washes and in serum. The induced antibodies demonstrated neutralizing effects on porcine rotavirus infection on MA104 cells. Our findings suggest that oral immunization with VP4-expressing L. lactis induced both specific local and systemic humoral and cellular immune responses in mice.
Collapse
|
10
|
Nayak B, Ray AR, Panda AK, Ray P. Improved Immunogenicity of Biodegradable Polymer Particles Entrapped Rotavirus Vaccine. J Biomater Appl 2010; 25:469-96. [DOI: 10.1177/0885328209353642] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Rotavirus (RV) entrapped in polylactide (PLA) and polylactide-coglycolide (PLGA) polymer particles were formulated and evaluated in mice for improved immunogenicity using oral, intranasal (IN), and intramuscular (IM) routes of administration. Microparticles of size ranges between 1 and 8 µm were prepared using double emulsion solvent evaporation technique. Stabilizers like mouse serum albumin, sucrose, and sodium bicarbonate that were used during particle formulation helped in minimizing the denaturation of the entrapped antigen. Immunization with 20 µg of antigen entrapped in polymeric particles through various routes of administration elicited measurable amount of antibody titer in mice. The immunoglobulin A (IgA) and immunoglobulin G (IgG) titer (≥4-fold rise between pre and post immunized sera) was analyzed by the use of enzyme-linked immunosorbent assay. PLGA encapsulated RV microparticles elicited better antibody response through IN route (90%) where as PLA encapsulated RV microparticles showed improved response when administrated through oral route (83.3%). Overall, the performance of IN route based immunization was significantly higher than oral and IM route ( p<0.001) with both the polymers. The results are of indication that, PLGA encapsulated RV microparticles have greater potential for vaccine formulation to combat rotavirus infection.
Collapse
Affiliation(s)
- Bismita Nayak
- Centre for Biomedical Engineering, Indian Institute of Technology Delhi New Delhi 110016, India, Centre for Biomedical Engineering, All India Institute of Medical Sciences, New Delhi 110029, India
| | - Alok R. Ray
- Centre for Biomedical Engineering, Indian Institute of Technology Delhi New Delhi 110016, India, Centre for Biomedical Engineering, All India Institute of Medical Sciences, New Delhi 110029, India,
| | - Amulya K. Panda
- Product Development Cell, National Institute of Immunology Aruna Asaf Ali Road, New Delhi 110067, India
| | - Pratima Ray
- Center for Diarrheal Disease Research, Department of Pediatrics All India Institute of Medical Sciences, New Delhi 110029, India
| |
Collapse
|
11
|
Dhama K, Chauhan RS, Mahendran M, Malik SVS. Rotavirus diarrhea in bovines and other domestic animals. Vet Res Commun 2009; 33:1-23. [PMID: 18622713 PMCID: PMC7088678 DOI: 10.1007/s11259-008-9070-x] [Citation(s) in RCA: 129] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/06/2008] [Indexed: 01/29/2023]
Abstract
Rotavirus diarrhea is the major cause of death of millions of children in developing countries besides causing economically significant malady in neonates of many domestic animals. In neonates, the infection is non-viremic, have very short incubation period, and manifests profuse diarrhea and severe dehydration. Concurrent infection with secondary pathogens may augment the disease severity. Diarrhea occurs due to virus-mediated destruction of absorption efficient enterocytes, activation of enteric nervous system, or due to a rotavirus enterotoxin. Diagnosis of the infection relies on conventional techniques like isolation in MA 104 cell lines, electron microscopy, electro-pherotyping, and various serological tests. Presently, diagnosis and molecular typing is performed using serotype specific RT-PCR, sequencing or genomic hybridization techniques. As the rotaviruses are known to exhibit extreme genetic diversity and outplay disinfection procedures, eradication of the pathogen is often difficult. Hence, for prevention, good management practices coupled with vaccination of dam for protecting young ones, has to be practiced. Recently, new generation prophylactic strategies including DNA vaccines, subunit vaccines, virus-like particles (VLPs) and edible vaccines have been found to induce sufficient levels of passive immunity. Aside to the infection in animals, zoonotic significance of the animal rotaviruses has to be further unearthed. In this review, efforts have been made to highlight the importance and prevalence of the disease in bovines, its pathogenesis along with preventive measures, salient features of rotaviruses and their inter-species transmission abilities, zoonotic implications, and a concise account of the infection in various domestic animals and poultry.
Collapse
Affiliation(s)
- K Dhama
- Division of Pathology, Indian Veterinary Research Institute, Izatnagar, Uttar Pradesh 243 122, India.
| | | | | | | |
Collapse
|
12
|
Bojsen A, Buesa J, Montava R, Kvistgaard AS, Kongsbak MB, Petersen TE, Heegaard CW, Rasmussen JT. Inhibitory activities of bovine macromolecular whey proteins on rotavirus infections in vitro and in vivo. J Dairy Sci 2008; 90:66-74. [PMID: 17183076 DOI: 10.3168/jds.s0022-0302(07)72609-7] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Rotavirus is a major cause of infantile viral gastroenteritis and can lead to severe and sometimes lethal dehydration. Previous studies have shown that breast-fed children are better protected against symptomatic infections, and that the milk fat globule protein lactadherin might be at least partly responsible for this effect. In vitro studies have shown that human lactadherin, in contrast to the bovine ortholog, could inhibit rotavirus infectivity, and that bovine MUC1 and a commercially available bovine macromolecular whey protein (MMWP) fraction proved to be effective. The present work describes the versatility of MMWP against the infection of 2 human intestinal cell lines (Caco-2 and FHs 74 Int) by 4 different rotavirus strains (Wa, RRV, YM, RF). Isolation of a protein fraction (CM3Q3) from MMWP that effectively inhibits rotavirus infectivity in vitro is documented. Purification was achieved by monitoring the rotaviral inhibitory activity in fractions obtained from 2 consecutive steps of ion-exchange chromatography. The major component of CM3Q3 was shown to be bovine IgG, and the attenuating capacity of this fraction is most properly linked to this component. The capacity of MMWP, MUC1, lactadherin, and the CM3Q3 fraction to inhibit the infectivity of the murine EMcN rotavirus strain was analyzed in adult BALB/c mice by using 2 different amounts of virus (10 and 100 times more than 50% the viral shedding doses). Only CM3Q3 was able to significantly affect the shedding of rotavirus in the stools of experimentally infected mice when the high viral dose was given. Detection of rotavirus-specific serum antibodies showed that the high dose infected all groups of mice. Experiments with the low dose of virus implied that all the tested milk proteins could affect the viral shedding in stools; in addition, use of MUC1, MMWP, and CM3Q3 prevented the appearance of serum viral antibodies. The advantages of using bovine immunoglobulins to induce passive immunity against rotavirus have been substantially investigated, although studies have mainly focused on the use of derivatives from immunized cows, especially colostrum. This report associates considerable activity against rotavirus infectivity with an ordinary whey product, suggesting that there might be alternatives to colostral-derived products.
Collapse
Affiliation(s)
- A Bojsen
- Protein Chemistry Laboratory, University of Aarhus, 8000 Aarhus C, Denmark
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Rodríguez-Díaz J, Rubilar-Abreu E, Spitzner M, Hedlund KO, Liprandi F, Svensson L. Design of a multiplex nested PCR for genotyping of the NSP4 from group A rotavirus. J Virol Methods 2008; 149:240-5. [PMID: 18353449 DOI: 10.1016/j.jviromet.2008.01.030] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2007] [Revised: 01/28/2008] [Accepted: 01/31/2008] [Indexed: 11/19/2022]
Abstract
A novel PCR method was developed to discriminate amongst genotypes A-C of the rotavirus non-structural protein 4 (NSP4). Genotype-specific primers were designed that correctly identified the NSP4 genotype when evaluated as a multiplex PCR with cell culture adapted rotavirus strains. Rotavirus strains B223 SGIG6P6[1], NCDV SGIG6P6[1] and SA11 SGIG3P5B[2] were used as control for NSP4 genotype A; A34 SGIG5P14[23], Gottfried SGIIG4P2B[6] and Wa SGIIG1P1A[8] for NSP4 genotype B; RRV SGIG3P5B[3] for NSP4 genotype C. Subsequently, the same set of specific primers was used to genotype a set of 77 Swedish clinical samples. The results showed that all human clinical samples analyzed belong to the NSP4 genotype B and the VP6 subgroup II.
Collapse
Affiliation(s)
- Jesús Rodríguez-Díaz
- Division of Molecular Virology, School of Medicine, Linköping University, Linköping, Sweden. ,
| | | | | | | | | | | |
Collapse
|
14
|
|
15
|
Klinman DM, Currie D, Lee G, Grippe V, Merkel T. Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax. Microbes Infect 2007; 9:1478-83. [PMID: 17913545 PMCID: PMC2117355 DOI: 10.1016/j.micinf.2007.08.002] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2007] [Revised: 07/26/2007] [Accepted: 08/03/2007] [Indexed: 11/19/2022]
Abstract
Improved vaccines and adjuvants are being developed to reduce the threat posed by a terrorist attack involving aerosolized anthrax spores. Nevertheless, uncertainty persists concerning the relative benefits of inducing mucosal vs systemic immunity to host survival following inhalational exposure to anthrax spores. This work examines the effect of delivering the licensed human vaccine (anthrax vaccine adsorbed, AVA) combined with a CpG oligodeoxynucleotide (ODN) adjuvant intraperitoneally or intranasally to A/J mice. Results indicate that protection from inhalational anthrax correlates with the induction of a strong systemic rather than mucosal immune response, and demonstrate that protection is significantly improved and accelerated by the addition of CpG ODN.
Collapse
Affiliation(s)
- Dennis M Klinman
- Laboratory of Experimental Immunology, National Cancer Institute, Frederick, MD 21702, USA.
| | | | | | | | | |
Collapse
|
16
|
Asensi MT, Martínez-Costa C, Buesa J. Anti-rotavirus antibodies in human milk: quantification and neutralizing activity. J Pediatr Gastroenterol Nutr 2006; 42:560-7. [PMID: 16707981 DOI: 10.1097/01.mpg.0000221892.59371.b3] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/10/2022]
Abstract
OBJECTIVE To analyze anti-rotavirus antibodies in human milk in order to determine their isotypes and neutralizing activity on rotavirus strains representing different viral serotypes. METHODS One hundred seventy-three milk samples (65 colostrum, 55 transitional milk and 53 mature milk) obtained from 65 mothers were analyzed along with 49 serum samples collected just before delivery. Total immunoglobulin A (IgA) and rotavirus-specific IgA and immunoglobulins G (IgG) antibodies were determined in milk and serum by enzyme-linked immunosorbent assay. Neutralizing activity was evaluated by an immunoperoxidase focus reduction assay. Milk IgA was purified by binding to the lectin jacalin, elution and ultrafiltration. RESULTS Total IgA antibodies were detected in all serum and milk samples analyzed. IgA levels decreased sharply during the replacement of colostrum by transitional milk, and more gradually from transitional to mature milk. These differences in IgA concentration during the 3 periods were statistically significant. Anti-rotavirus antibodies detected in human milk were exclusively of the IgA type, whereas both IgA and IgG anti-rotavirus antibodies were present in serum samples. Both milk and serum samples showed in vitro neutralization of the infectivity of rotavirus strains SA11, Wa and VA70, this activity being stronger toward the human rotavirus strain Wa. No correlation was however found between the inhibitory effect on rotavirus and the concentrations of IgA in human milk and serum samples. CONCLUSION Anti-rotavirus antibodies are only partly responsible for the neutralizing activity detected in milk and serum. This result suggests that other components possessing suppressive activity against rotavirus must also be present.
Collapse
Affiliation(s)
- María Teresa Asensi
- Department of Pediatrics, School of Medicine and Hospital Clínico Universitario, University of Valencia, Avenida Blasco Ibáñez, 17, 46010 Valencia, Spain
| | | | | |
Collapse
|
17
|
Soler E, Le Saux A, Guinut F, Passet B, Cohen R, Merle C, Charpilienne A, Fourgeux C, Sorel V, Piriou A, Schwartz-Cornil I, Cohen J, Houdebine LM. Production of Two Vaccinating Recombinant Rotavirus Proteins in the Milk of Transgenic Rabbits. Transgenic Res 2005; 14:833-44. [PMID: 16315090 DOI: 10.1007/s11248-005-1771-0] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2005] [Accepted: 08/05/2005] [Indexed: 10/25/2022]
Abstract
Rotaviruses are the main cause of infantile viral gastroenteritis worldwide leading to approximately 500,000 deaths each year mostly in the developing world. For unknown reasons, live attenuated viruses used in classical vaccine strategies were shown to be responsible for intussusception (a bowel obstruction). New strategies allowing production of safe recombinant non-replicating rotavirus candidate vaccine are thus clearly needed. In this study we utilized transgenic rabbit milk as a source of rotavirus antigens. Individual transgenic rabbit lines were able to produce several hundreds of micrograms per ml of secreted recombinant VP2 and VP6 proteins in their milk. Viral proteins expressed in our model were immunogenic and were shown to induce a significant reduction in viral antigen shedding after challenge with virulent rotavirus in the adult mouse model. To our knowledge, this is the first report of transgenic mammal bioreactors allowing the rapid co-production of two recombinant viral proteins in milk to be used as a vaccine.
Collapse
Affiliation(s)
- Eric Soler
- Biologie du Développement et de la Reproduction, INRA, bât.440, Jouy-en-Josas, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Dong JL, Liang BG, Jin YS, Zhang WJ, Wang T. Oral immunization with pBsVP6-transgenic alfalfa protects mice against rotavirus infection. Virology 2005; 339:153-63. [PMID: 15992851 DOI: 10.1016/j.virol.2005.06.004] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2004] [Revised: 03/11/2005] [Accepted: 06/01/2005] [Indexed: 10/25/2022]
Abstract
A critical factor in edible plant-derived vaccine development is adequate expression of the exogenous antigens in transgenic plants. We synthesized a codon-optimized gene (sVP6) encoding the VP6 protein of human group A rotavirus and inserted it into the alfalfa genome using agrobacterium-mediated transformation. As much as 0.28% of the total soluble protein of the pBsVP6-transgenic alfalfa was sVP6. Female BALB/c mice were gavaged weekly with 10 mg of transgenic alfalfa extract containing 24 microg of sVP6 protein and 10 microg of CpG-rich oligodeoxynucleotides as mucosal adjuvant. Immunized mice developed high titers of anti-VP6 serum IgG and mucosal IgA. Offspring of immunized dams developed less severe diarrhea after challenge with simian rotavirus SA-11, indicating that antibodies generated in the dams provided passive heterotypic protection to the pups. These results suggest that oral immunization with pBsVP6-transgenic alfalfa provides a potential means of protecting children and young animals from severe acute rotavirus-induced diarrhea.
Collapse
Affiliation(s)
- Jiang-Li Dong
- State Key Laboratory of Agrobiotechnology, China Agricultural University, 2 Yuanmingyuan West Road, Haidian District, Beijing 100094, China.
| | | | | | | | | |
Collapse
|